MX2019003225A - Proteínas de unión a cd123 y composiciones y métodos relacionados. - Google Patents
Proteínas de unión a cd123 y composiciones y métodos relacionados.Info
- Publication number
- MX2019003225A MX2019003225A MX2019003225A MX2019003225A MX2019003225A MX 2019003225 A MX2019003225 A MX 2019003225A MX 2019003225 A MX2019003225 A MX 2019003225A MX 2019003225 A MX2019003225 A MX 2019003225A MX 2019003225 A MX2019003225 A MX 2019003225A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- methods
- binds
- binding domain
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397736P | 2016-09-21 | 2016-09-21 | |
| US201762466192P | 2017-03-02 | 2017-03-02 | |
| PCT/US2017/052808 WO2018057802A1 (en) | 2016-09-21 | 2017-09-21 | Cd123 binding proteins and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003225A true MX2019003225A (es) | 2019-06-10 |
Family
ID=61690646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003225A MX2019003225A (es) | 2016-09-21 | 2017-09-21 | Proteínas de unión a cd123 y composiciones y métodos relacionados. |
| MX2022015847A MX2022015847A (es) | 2016-09-21 | 2019-03-20 | Proteinas de union a cd123 y composiciones y metodos relacionados. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015847A MX2022015847A (es) | 2016-09-21 | 2019-03-20 | Proteinas de union a cd123 y composiciones y metodos relacionados. |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| CN114040926B (zh) | 2019-05-04 | 2025-07-29 | 印希比生物科学有限公司 | 结合cd123的多肽及其用途 |
| EP3753954A1 (en) * | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
| MX2022001882A (es) * | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| CN110804096B (zh) * | 2019-11-21 | 2021-07-06 | 深圳普瑞金生物药业有限公司 | Cd123单域抗体、核苷酸序列、表达载体及试剂盒 |
| US20230151102A1 (en) * | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| CN115279406A (zh) * | 2020-01-13 | 2022-11-01 | 阿帕特夫研究和发展有限公司 | 蛋白质治疗剂的调配物 |
| CN111171155B (zh) | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
| CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| AU2021390501A1 (en) * | 2020-12-01 | 2023-06-29 | Aptevo Research And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| CN117255807A (zh) * | 2020-12-31 | 2023-12-19 | 赛诺菲 | 与NKp46和CD123结合的多功能自然杀伤（NK）细胞接合器 |
| EP4294829A4 (en) * | 2021-02-17 | 2025-03-19 | IGM Biosciences Inc. | ANTI-CD123 BINDING MOLECULES AND THEIR USES |
| US20240262920A1 (en) * | 2021-05-21 | 2024-08-08 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
| CN116162148B (zh) * | 2021-11-24 | 2025-09-09 | 中山光度生物医药有限公司 | 多特异性配体结合分子及其应用 |
| CN116836282B (zh) * | 2023-02-13 | 2024-03-29 | 北京艺妙神州医药科技有限公司 | 抗体、嵌合抗原受体及其用途 |
| CN117660325B (zh) * | 2024-01-31 | 2024-04-19 | 苏州科为康生物医药科技有限公司 | 一种制备脐带血msc的培养基及其方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| AU2002329647A1 (en) | 2001-07-26 | 2003-02-24 | University Of Utah Research Foundation | In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation |
| CN102093477B (zh) | 2002-05-22 | 2014-02-26 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| EP1711527A4 (en) * | 2003-12-15 | 2008-09-03 | Dendreon Corp | HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS |
| AU2006210660B2 (en) | 2005-02-01 | 2011-12-01 | Morphosys Ag | Libraries and methods for isolating antibodies |
| JP2008539785A (ja) * | 2005-05-16 | 2008-11-20 | モルフォテック、インク． | 所望の表現型を示す細胞を選択するために制御されたベクター |
| US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US7949480B2 (en) | 2006-06-14 | 2011-05-24 | Simphotek, Inc. | Method for determining an interaction between an electromagnetic radiation and a material |
| HRP20160082T1 (hr) * | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| US9364557B2 (en) | 2007-08-01 | 2016-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fold-back diabody diphtheria toxin immunotoxin and methods of use |
| MX2011003502A (es) * | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| ES2550639T3 (es) * | 2009-04-27 | 2015-11-11 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre |
| SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
| IN2014MN02293A (cg-RX-API-DMAC10.html) * | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| EP2850106B1 (en) * | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| TWI701258B (zh) * | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| AR103488A1 (es) * | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| US20180022819A1 (en) * | 2015-02-11 | 2018-01-25 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| HK1251480A1 (zh) * | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| EP3464365A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
| EP3515491A4 (en) * | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| US20230151102A1 (en) | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| CN115279406A (zh) | 2020-01-13 | 2022-11-01 | 阿帕特夫研究和发展有限公司 | 蛋白质治疗剂的调配物 |
-
2017
- 2017-09-21 EP EP17853936.7A patent/EP3515491A4/en active Pending
- 2017-09-21 BR BR112019005333-6A patent/BR112019005333A2/pt active Search and Examination
- 2017-09-21 CN CN201780069428.3A patent/CN109952112B/zh active Active
- 2017-09-21 US US16/335,561 patent/US11242400B2/en active Active
- 2017-09-21 CA CA3037688A patent/CA3037688A1/en active Pending
- 2017-09-21 PH PH1/2019/500609A patent/PH12019500609B1/en unknown
- 2017-09-21 KR KR1020197011271A patent/KR102559732B1/ko active Active
- 2017-09-21 SG SG10202102846SA patent/SG10202102846SA/en unknown
- 2017-09-21 MX MX2019003225A patent/MX2019003225A/es unknown
- 2017-09-21 UA UAA201904226A patent/UA127450C2/uk unknown
- 2017-09-21 MY MYPI2019001301A patent/MY194290A/en unknown
- 2017-09-21 WO PCT/US2017/052808 patent/WO2018057802A1/en not_active Ceased
- 2017-09-21 JP JP2019537049A patent/JP7224289B2/ja active Active
- 2017-09-21 AU AU2017331256A patent/AU2017331256B2/en active Active
- 2017-09-21 IL IL265484A patent/IL265484B2/en unknown
-
2018
- 2018-03-22 US US15/933,324 patent/US10676533B2/en active Active
-
2019
- 2019-03-20 MX MX2022015847A patent/MX2022015847A/es unknown
- 2019-04-12 ZA ZA2019/02323A patent/ZA201902323B/en unknown
- 2019-04-19 CO CONC2019/0003951A patent/CO2019003951A2/es unknown
-
2021
- 2021-12-21 US US17/557,440 patent/US11939392B2/en active Active
-
2023
- 2023-02-07 JP JP2023016697A patent/JP2023058573A/ja active Pending
-
2024
- 2024-02-15 US US18/442,779 patent/US12441798B2/en active Active
-
2025
- 2025-09-23 US US19/337,579 patent/US20260234254A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
| BR112018009972A2 (pt) | ligantes de ctla4 | |
| CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
| AR105444A1 (es) | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| ECSP19011185A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 | |
| BR112016027912A2 (pt) | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer | |
| BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
| MX2019001469A (es) | Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2. | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| BR112018073289A2 (pt) | moléculas de ligação, polinucleotídeo isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| CO6571892A2 (es) | Composiciones y métodos para el diagnostico y tratamiento de tumores | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
| BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| UA122479C2 (uk) | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) | |
| MX2016014000A (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos |